A new direct acting antiviral (DAA) combo for hepatitis c infection is more effective than sofosbuvir and peg-interferon plus ribavirin, according to new data presented this week at the International Liver Congress taking place in Barcelona, Spain.
US pharma giant Merck & Co (NYSE: MRK) presented results from C-EDGE Head-to-Head, the company’s comparative, Phase III, open-label clinical trial evaluating the efficacy and safety of Zepatier (elbasvir and grazoprevir) 50mg/100mg tablets versus a regimen of sofosbuvir 400mg tablets plus peginterferon and ribavirin (pegIFN/RBV) in treatment-naïve and pegIFN/RBV treatment-experienced patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infection (abstract #PS002).
In this study, Zepatier, which was just approved by the US Food and Drug Administration in January, demonstrated superiority on efficacy and safety endpoints compared to sofosbuvir plus pegIFN/RBV, based on pre-specified analyses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze